Patents Assigned to Inflarx GmbH
-
Patent number: 11999698Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.Type: GrantFiled: September 9, 2021Date of Patent: June 4, 2024Assignee: InflaRx GmbHInventors: Yong Li, Renfeng Guo, Niels Christoph Riedemann
-
Patent number: 11890349Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: GrantFiled: November 2, 2020Date of Patent: February 6, 2024Assignee: InflaRx GmbHInventors: Renfeng Guo, Niels C. Riedemann
-
Publication number: 20230279087Abstract: The present invention relates to antibodies that specifically bind to a conformational epitope of human C5a. The invention particularly relates to humanized anti-C5a antibodies. The antibodies described herein are useful as active agents in pharmaceutical compositions. The antibodies and pharmaceutical compositions are especially useful for the treatment and prevention of diseases or disorders involving pathological C5a activity.Type: ApplicationFiled: May 6, 2021Publication date: September 7, 2023Applicant: InflaRx GmbHInventors: Renfeng GUO, Niels C. RIEDEMANN
-
Publication number: 20230158060Abstract: The present invention relates to an inhibitor of C5a activity medical condition caused by or associated with infection with a corona virus. The invention also relates to the use of an inhibitor of C5a activity in the reduction of an inflammatory response in a subject suffering from a corona virus infection. The invention further relates to an inhibitor of C5a activity for use in the improvement of organ function, in particular lung function and/or hepatic function, in a subject suffering from a corona virus infection.Type: ApplicationFiled: March 27, 2020Publication date: May 25, 2023Applicant: InflaRx GmbHInventors: Niels C. RIEDEMANN, Renfeng GUO
-
Patent number: 11464868Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: GrantFiled: August 7, 2019Date of Patent: October 11, 2022Assignee: InflaRx GmbHInventors: Renfeng Guo, Niels C. Riedemann
-
Patent number: 11273225Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: GrantFiled: June 13, 2018Date of Patent: March 15, 2022Assignee: InflaRx GmbHInventors: Renfeng Guo, Niels R. Riedemann
-
Publication number: 20210403433Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.Type: ApplicationFiled: September 9, 2021Publication date: December 30, 2021Applicant: InflaRx GmbHInventors: YONG LI, RENFENG GUO, NIELS CHRISTOPH RIEDEMANN
-
Patent number: 11149009Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.Type: GrantFiled: February 7, 2020Date of Patent: October 19, 2021Assignee: InflaRx GmbHInventors: Yong Li, Renfeng Guo, Niels Christoph Riedemann
-
Publication number: 20210046191Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: ApplicationFiled: November 2, 2020Publication date: February 18, 2021Applicant: InflaRx GmbHInventors: Renfeng Guo, Niels C. Riedemann
-
Patent number: 10858421Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.Type: GrantFiled: January 24, 2019Date of Patent: December 8, 2020Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Christoph Riedemann
-
Publication number: 20200290969Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.Type: ApplicationFiled: February 7, 2020Publication date: September 17, 2020Applicant: InflaRx GmbHInventors: YONG LI, RENFENG GUO, NIELS CHRISTOPH RIEDEMANN
-
Patent number: 10774136Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: September 16, 2016Date of Patent: September 15, 2020Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
-
Publication number: 20200061202Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: ApplicationFiled: August 7, 2019Publication date: February 27, 2020Applicant: InflaRx GmbHInventors: Renfeng Guo, Niels C. Riedemann
-
Patent number: 10376595Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: GrantFiled: June 13, 2018Date of Patent: August 13, 2019Assignee: InflaRx GmbHInventors: Renfeng Guo, Niels C. Riedemann
-
Patent number: 10227397Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.Type: GrantFiled: March 20, 2015Date of Patent: March 12, 2019Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Christoph Riedemann
-
Publication number: 20180280530Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: ApplicationFiled: June 13, 2018Publication date: October 4, 2018Applicant: InflaRx GmbHInventors: Renfeng Guo, Niels R. Riedemann
-
Publication number: 20180282425Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.Type: ApplicationFiled: June 13, 2018Publication date: October 4, 2018Applicant: InflaRx GmbHInventors: Renfeng Guo, Niels R. Riedemann
-
Publication number: 20170137499Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.Type: ApplicationFiled: March 20, 2015Publication date: May 18, 2017Applicant: INFLARX GMBHInventors: Renfeng GUO, Niels Christoph RIEDEMANN
-
Patent number: 9458233Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: June 3, 2015Date of Patent: October 4, 2016Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
-
Patent number: 9073983Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: June 27, 2014Date of Patent: July 7, 2015Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Cristoph Riedemann, Yan Li, Beifen Shen